

Product Data Sheet

Product Name: KW-8232 free base
 Cat. No.: GC31633

Chemical Properties

Cas. No. 170365-25-0

SMILES O=C(C(N1CCN(C)C)=C(C(C2=CC=C(O)C=C2)C3=CC=C(O)C=C3)C4=C1C=CC=C4)N5CCN(C6=CC=CC=C6Cl)CC5

Formula C₃₆H₃₇ClN₄O₃

M.Wt

609.16

Solubility Soluble in DMSO

Storage

Store at -20°C

General For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure

Protocol

Animal experiment:

After male Sprague-Dawley rats (5-week-old) are anesthetized with sodium pentobarbital (30 mg/kg, i.p.), a dorsolateral incision is made on the right hip through which the sciatic nerve is exposed, and a 0.5-cm section is excised. The contralateral leg is left intact. KW-8232 is dissolved in distilled water and administered orally at 1, 3, 10, and 30 mg/kg once daily beginning 1 day prior to neurectomy. On day 28, rats are exsanguinated under diethyl ether after obtaining urine, and their femurs are removed. Bone mineral density (BMD) is determined by dual energy x-ray absorptiometry. Twenty-four hour urine samples are collected from the animals, which are fasted immediately after the final administration of KW-8232[1].

References:

[1]. Uchii M, et al.
 Effect of KW-8232, a novel anti-osteoporotic agent, on bone loss in sciatic neurectomized rats.
 Jpn J Pharmacol.
 1998 Oct;78(2):241-3.

Background

KW-8232 free base is an anti-osteoporotic agent, and can reduce the biosynthesis of PGE₂.

KW-8232 free base is an anti-osteoporotic agent. KW-8232 reduces the biosynthesis of PGE₂ in mouse osteoblastic cells[1].

KW-8232 (3, 10, 30 mg/kg, p.o.) potently increases the femoral bone mineral density (BMD) of immobilized legs of rats, and affects immobilization-induced abnormal bone turnover. KW-8232 markedly decreases urinary calcium excretion in the neurectomized rats only at 30 mg/kg, and highly reduces urinary pyridinoline and deoxypyridinoline excretion which are

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

markers of bone resorption in neurectomized rats. KW-8232 inhibits bone loss may be attributed to the lower prostaglandins (PGs)-stimulated bone resorption via regulation of PGE2 production[1].

[1]. Uchii M, et al. Effect of KW-8232, a novel anti-osteoporotic agent, on bone loss in sciatic neurectomized rats. Jpn J Pharmacol. 1998 Oct;78(2):241-3.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA